Role of albumin-bilirubin score in non-malignant liver disease

The albumin-bilirubin (ALBI) score, which was proposed to assess the prognosis of patients with hepatocellular carcinoma, has gradually been extended to other liver diseases in recent years, including primary biliary cholangitis, liver cirrhosis, hepatitis, liver transplantation, and liver injury. T...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG 2024-03, Vol.30 (9), p.999-1004
Main Authors: Xu, Shi-Xue, Yang, Fan, Ge, Nan, Guo, Jin-Tao, Sun, Si-Yu
Format: Article
Language:English
Subjects:
Bilirubin
Carcinoma, Hepatocellular - pathology
End Stage Liver Disease - diagnosis
End Stage Liver Disease - surgery
Humans
Liver Neoplasms - pathology
Prognosis
Retrospective Studies
Serum Albumin
Severity of Illness Index
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The albumin-bilirubin (ALBI) score, which was proposed to assess the prognosis of patients with hepatocellular carcinoma, has gradually been extended to other liver diseases in recent years, including primary biliary cholangitis, liver cirrhosis, hepatitis, liver transplantation, and liver injury. The ALBI score is often compared with classical scores such as the Child-Pugh and model for end-stage liver disease scores or other noninvasive prediction models. It is widely employed because of its immunity to subjective evaluation indicators and ease of obtaining detection indicators. An increasing number of studies have confirmed that it is highly accurate for assessing the prognosis of patients with chronic liver disease; additionally, it has demonstrated good predictive performance for outcomes beyond survival in patients with liver diseases, such as decompensation events. This article presents a review of the application of ALBI scores in various non-malignant liver diseases.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v30.i9.999